Alergologia Polska - Polish Journal of Allergology

Switching inhalers for non-clinical reasons: more benefits or drawbacks?

Marta Miszczuk-Cieśla 1
,
Izabela Domagała-Mańczyk 1
,
Marta Maskey-Warzęchowska 1
,
Marta Dąbrowska 1

  1. Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland

Alergologia Polska – Polish Journal of Allergology

DOI: https://doi.org/10.5114/pja.2026.163796
Data publikacji online: 2026/08/03
Article file
PJA Switching.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204-22.
  2. Zhang L, Jiang H, Yang G, et al. Global, regional and national burden of asthma from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMJ Open Respir Res 2025; 12(1).
  3. Al Wachami N, Guennouni M, Iderdar Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health 2024; 24: 297.
  4. de Oca MM, Perez-Padilla R, Celli B, et al. The global burden of COPD: epidemiology and effect of prevention strategies. Lancet Respir Med 2025; 13: 709-24.
  5. Wurzel DF, Montgomery BD, Anderson N, et al. Environmental impact of inhaled medicines: a Thoracic Society of Australia and New Zealand position statement. Respirology 2025; 30: 101-12.
  6. Global Strategy For Prevention, Diagnosis And Management Of COPD: 2025 Report [Available from: https://goldcopd.org/2025-gold-report/].
  7. Global Strategy for Asthma Management and Prevention 2025 [Available from: http://www.ginaasthma.org].
  8. Usmani OS, Bosnic-Anticevich S, Dekhuijzen R, et al. Real-world impact of nonclinical inhaler regimen switches on asthma or COPD: a systematic review. J Allergy Clin Immunol Pract 2022; 10: 2624-37.
  9. Usmani OS, Hickey AJ, Guranlioglu D, et al. The impact of inhaler device regimen in patients with asthma or COPD. J Allergy Clin Immunol Pract 2021; 9: 3033-40 e1.
  10. Bloom CI, Douglas I, Olney J, et al. Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax 2019; 74: 1078-86.
  11. Voorham J, Roche N, Benhaddi H, et al. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open 2018; 8: e022051.
  12. McCarthy P, Iliadis T, Zaiken K. Clinical response and cost-savings associated with generic fluticasone propionate/salmeterol multidose, dry-powder inhaler in asthma patients managed in an ambulatory care practice setting. J Pharm Pract 2022; 35: 274-80.
  13. Nagasaki K, Kaji Y, Wada Y, Sasaki T. The environmental impact of inhaler replacement: a carbon footprint and economic calculation of the National Database of Health Insurance Claims in Japan. J Gen Fam Med 2023; 24: 207-14.
  14. Setayeshgar S, Liang KE, Stoynova V, et al. Modelling the climate impact of inhalers and mitigation strategies: a population-based study in British Columbia, Canada (2015-2032). BMJ Open Respir Res 2025; 12(1).
  15. Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. NPJ Prim Care Respir Med 2023; 33: 24.
  16. Keeley D, Scullion JE, Usmani OS. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. Eur Respir J 2020; 55: 2000048.
  17. Arslan IG, Vervloet M, de Bekker-Grob EW, et al. The role of environmental impact in healthcare providers’ choices of inhalers for treatment of asthma and COPD: a discrete choice experiment. BMC Prim Care 2025; 26: 278.
  18. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1: 356-63.
  19. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J 2018; 2018: 2732017.
  20. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag 2019; 15: 461-72.
  21. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res 2018; 19: 10.
  22. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930-8.
  23. Kocks JWH, Chrystyn H, van der Palen J, et al. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ Prim Care Respir Med 2018; 28: 43.
  24. Rodriguez-Garcia C, Barreiro E, Munoz-Gall X, et al. Common errors in inhalation therapy: impact and solutions. Clin Respir J 2020; 14: 1001-10.
  25. Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement T. Systematic review of errors in inhaler use: has patient technique improved over time? Chest 2016; 150: 394-406.
  26. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J 2017; 49: 1601794.
  27. Cataldo D, Hanon S, Peche RV, et al. How to choose the right inhaler using a patient-centric approach? Adv Ther 2022; 39: 1149-63.
  28. Lavorini F, Janson C, Braido F, et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis 2019; 13: 1753466619884532.
  29. Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med 2016; 118: 65-75.
  30. Kocks JWH, Wouters H, Bosnic-Anticevich S, et al. Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers. NPJ Prim Care Respir Med 2022; 32: 18.
  31. Basheti IA, Obeidat NM, Reddel HK. Inhaler technique education and asthma control among patients hospitalized for asthma in Jordan. Saudi Pharm J 2018; 26: 1127-36.
  32. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2017; 12: 59-71.
  33. Munoz X, Giner J, Sicras A, Lo Re D. Maintenance inhalers for asthma and COPD in Spain. Respir Care 2024; 69: 1534-42.
  34. Albanna AS, Alhajji M, Alsowayan W, Soliman MH. The impact of unsupervised and unconsented switch of inhalers in patients with controlled asthma – a targeted literature review. Ann Thorac Med 2023; 18: 103-15.
  35. Sola-Morales O, Soriano JB, Solozabal-Coll M, Galindo JV. An estimation of the economic and environmental impact of inhaler devices switch for non-clinical reasons in COPD and asthma: the case for Spain. J Mark Access Health Policy 2025; 13: 34.
  36. Principe S, Battaglia S, Benfante A, et al. Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma? J Asthma 2022; 59: 370-7.
  37. Ekberg-Jansson A, Svenningsson I, Ragdell P, et al. Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE). Int J Clin Pract 2015; 69: 1171-8.
  38. Sangiorgi D, Perrone V, Buda S, et al. Exacerbations in COPD patients treated with inhaled corticosteroids/long-acting β2 agonists combinations, switching to another combination drugs or inhaler device: a “real – world” study. Cogent Med 2017; 4: 1304873.
  39. Lewis A, Torvinen S, Dekhuijzen PN, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res 2016; 16: 251.
  40. Bjornsdottir US, Sigurethardottir ST, Jonsson JS, et al. Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting beta(2) -agonists in obstructive lung diseases: a population-based, observational study. Int J Clin Pract 2014; 68: 812-9.
  41. Lavorini F, Ninane V, Haughney J, et al. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin Drug Deliv 2013; 10: 1597-602.
  42. Kaplan A, van Boven JFM. Switching inhalers: a practical approach to keep on UR RADAR. Pulm Ther 2020; 6: 381-92.
  43. Tervonen T, Hawken N, Hanania NA, et al. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax 2020; 75: 735-43.
  44. Pirozynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin Drug Deliv 2016; 13: 1559-71.
  45. Plaza V, Giner J, Rodrigo GJ, et al. Errors in the use of inhalers by health care professionals: a systematic review. J Allergy Clin Immunol Pract 2018; 6: 987-95.
  46. Guevara DL, Bernard S, Manhood S, et al. Prognostic value of interim PET/CT in non-Hodgkin lymphoma. Rev Med Chil 2020; 148: 1558-67.
  47. Booker R. Do patients think that dry powder inhalers can be used interchangeably? Int J Clin Pract Suppl 2005; 149: 30-2.
  48. Ray SE, Boudewyns V, Davis C, et al. Patient perceptions of switching to a generic dry powder inhaler - increased understanding through journey mapping. Int J Chron Obstruct Pulmon Dis 2022; 17: 1751-68.
  49. Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their consent? Prim Care Respir J 2010; 19: 131-9.
  50. Gilbert I, Wada K, Burudpakdee C, et al. The impact of a forced non-medical switch of inhaled respiratory medication among patients with asthma or chronic obstructive pulmonary disease: a patient survey on experience with switch, therapy satisfaction, and disease control. Patient Prefer Adherence 2020; 14: 1463-75.
  51. Meng W, Xiong R, Zhao Z, et al. Suboptimal peak inspiratory flow rate: a noticeable risk factor for inhaler concordance in patients with chronic airway diseases. BMJ Open Respir Res 2024; 11(1).
  52. George M. Adherence in asthma and COPD: new strategies for an old problem. Respir Care 2018; 63: 818-31.
  53. Peirce AM, Hogan CK, Weinstein JB, et al. Clinician views on inhaler substitution in the Veterans Health Administration. Chest 2025: S 0012-3692(25)05799-X.
  54. Art. 44. Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych [Available from: https://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20111220696/T/D20110696L.pdf].
  55. European Medicines Agency. Guideline on the investigation of bioequivalence. [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf].
  56. Drozdowska A, Hermanowski T. Exploring factors underlying the attitude of community pharmacists to generic substitution: a nationwide study from Poland. Int J Clin Pharm 2016; 38: 162-70.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications